Latest News

CAPTAIN trial data showed TULSA preserved penile length, continence, and erectile function compared with robotic prostatectomy in localized prostate cancer.

In this episode, Jason Hafron, MD, explains how data-driven pathways and patient follow-up systems can improve quality and outcomes in urologic oncology.

Can Aydogdu, MD, highlights a study examining the utility of pre-surgical tumor-informed ctDNA to predict pathologic nodal status at radical cystectomy.

The PDUFA target action date is in the fourth quarter of 2026.

The study showed that perioperative EV–pembrolizumab improved EFS, OS, and pCR rate vs neoadjuvant cisplatin-gemcitabine in patients with MIBC who are eligible for cisplatin-based chemotherapy.

Experts discuss practical strategies to improve the detection of CIS through closer urologist-pathologist collaboration, optimized biopsy techniques, and complementary diagnostic tools.

Olaparib's indications in the US include use as a single agent for patients with HRR gene-mutated mCRPC and in combination with abiraterone and prednisone for patients with BRCA-mutated mCRPC.

These results provided the basis for the ongoing randomized phase 3 ProstACT Global trial evaluating 177Lu-rosopatamab tetraxetan in mCRPC.

Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol, discusses the clinical significance of the phase 3 PROTEUS trial and addresses concerns about the study's use of ADT in the control arm.

Experts discuss why CIS is frequently underrecognized, highlighting the subtle clinical and cystoscopic features of the disease and the importance of integrating multiple factors to improve detection.

This marks the first phase 3 study of a targeted radiopharmaceutical therapy in clear cell renal cell carcinoma.

Tyler S. Garman, MD, highlights phase 2 data on intravesical gemcitabine and docetaxel as first-line treatment of BCG‒naïve NMIBC.

Results from a first-in-human phase 0 feasibility trial showed that combined bladder and kidney transplantation was technically feasible.